Global Anti-VEGF Drug Supply, Demand and Key Producers, 2023-2029

February 2023 | 97 pages | ID: GB1B8E12EBDDEN
GlobalInfoResearch

Abstracts

The global Anti-VEGF Drug market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).

This report studies the global Anti-VEGF Drug production, demand, key manufacturers, and key regions.

This report is a detailed and comprehensive analysis of the world market for Anti-VEGF Drug, and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Anti-VEGF Drug that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global Anti-VEGF Drug total production and demand, 2018-2029, (K Units)

Global Anti-VEGF Drug total production value, 2018-2029, (USD Million)

Global Anti-VEGF Drug production by region & country, production, value, CAGR, 2018-2029, (USD Million) & (K Units)

Global Anti-VEGF Drug consumption by region & country, CAGR, 2018-2029 & (K Units)

U.S. VS China: Anti-VEGF Drug domestic production, consumption, key domestic manufacturers and share

Global Anti-VEGF Drug production by manufacturer, production, price, value and market share 2018-2023, (USD Million) & (K Units)

Global Anti-VEGF Drug production by Type, production, value, CAGR, 2018-2029, (USD Million) & (K Units)

Global Anti-VEGF Drug production by Application production, value, CAGR, 2018-2029, (USD Million) & (K Units)

This reports profiles key players in the global Anti-VEGF Drug market based on the following parameters – company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include F. Hoffmann-La Roche Ltd, Amgen Inc, Pfizer, Inc, Xbrane Biopharma AB, Allergan, Bayer AG, Regeneron Pharmaceuticals Inc. and Viatris Inc, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Anti-VEGF Drug market

Detailed Segmentation:

Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.

Global Anti-VEGF Drug Market, By Region:

• United States
• China
• Europe
• Japan
• South Korea
• ASEAN
• India
• Rest of World

Global Anti-VEGF Drug Market, Segmentation by Type

• Avastin
• Lucentis
• Eylea

Global Anti-VEGF Drug Market, Segmentation by Application

• Age-related Macular Degeneration
• Macular Edema Following Retinal Vein Occlusion
• Diabetic Macular Edema
• Diabetic Retinopathy

Companies Profiled:

• F. Hoffmann-La Roche Ltd
• Amgen Inc
• Pfizer, Inc
• Xbrane Biopharma AB
• Allergan
• Bayer AG
• Regeneron Pharmaceuticals Inc.
• Viatris Inc

Key Questions Answered

1. How big is the global Anti-VEGF Drug market?

2. What is the demand of the global Anti-VEGF Drug market?

3. What is the year over year growth of the global Anti-VEGF Drug market?

4. What is the production and production value of the global Anti-VEGF Drug market?

5. Who are the key producers in the global Anti-VEGF Drug market?

6. What are the growth factors driving the market demand?

Contents

1 SUPPLY SUMMARY

1.1 Anti-VEGF Drug Introduction
1.2 World Anti-VEGF Drug Supply & Forecast
  1.2.1 World Anti-VEGF Drug Production Value (2018 & 2022 & 2029)
  1.2.2 World Anti-VEGF Drug Production (2018-2029)
  1.2.3 World Anti-VEGF Drug Pricing Trends (2018-2029)
1.3 World Anti-VEGF Drug Production by Region (Based on Production Site)
  1.3.1 World Anti-VEGF Drug Production Value by Region (2018-2029)
  1.3.2 World Anti-VEGF Drug Production by Region (2018-2029)
  1.3.3 World Anti-VEGF Drug Average Price by Region (2018-2029)
  1.3.4 North America Anti-VEGF Drug Production (2018-2029)
  1.3.5 Europe Anti-VEGF Drug Production (2018-2029)
  1.3.6 China Anti-VEGF Drug Production (2018-2029)
  1.3.7 Japan Anti-VEGF Drug Production (2018-2029)
1.4 Market Drivers, Restraints and Trends
  1.4.1 Anti-VEGF Drug Market Drivers
  1.4.2 Factors Affecting Demand
  1.4.3 Anti-VEGF Drug Major Market Trends
1.5 Influence of COVID-19 and Russia-Ukraine War
  1.5.1 Influence of COVID-19
  1.5.2 Influence of Russia-Ukraine War

2 DEMAND SUMMARY

2.1 World Anti-VEGF Drug Demand (2018-2029)
2.2 World Anti-VEGF Drug Consumption by Region
  2.2.1 World Anti-VEGF Drug Consumption by Region (2018-2023)
  2.2.2 World Anti-VEGF Drug Consumption Forecast by Region (2024-2029)
2.3 United States Anti-VEGF Drug Consumption (2018-2029)
2.4 China Anti-VEGF Drug Consumption (2018-2029)
2.5 Europe Anti-VEGF Drug Consumption (2018-2029)
2.6 Japan Anti-VEGF Drug Consumption (2018-2029)
2.7 South Korea Anti-VEGF Drug Consumption (2018-2029)
2.8 ASEAN Anti-VEGF Drug Consumption (2018-2029)
2.9 India Anti-VEGF Drug Consumption (2018-2029)

3 WORLD ANTI-VEGF DRUG MANUFACTURERS COMPETITIVE ANALYSIS

3.1 World Anti-VEGF Drug Production Value by Manufacturer (2018-2023)
3.2 World Anti-VEGF Drug Production by Manufacturer (2018-2023)
3.3 World Anti-VEGF Drug Average Price by Manufacturer (2018-2023)
3.4 Anti-VEGF Drug Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
  3.5.1 Global Anti-VEGF Drug Industry Rank of Major Manufacturers
  3.5.2 Global Concentration Ratios (CR4) for Anti-VEGF Drug in 2022
  3.5.3 Global Concentration Ratios (CR8) for Anti-VEGF Drug in 2022
3.6 Anti-VEGF Drug Market: Overall Company Footprint Analysis
  3.6.1 Anti-VEGF Drug Market: Region Footprint
  3.6.2 Anti-VEGF Drug Market: Company Product Type Footprint
  3.6.3 Anti-VEGF Drug Market: Company Product Application Footprint
3.7 Competitive Environment
  3.7.1 Historical Structure of the Industry
  3.7.2 Barriers of Market Entry
  3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations

4 UNITED STATES VS CHINA VS REST OF THE WORLD

4.1 United States VS China: Anti-VEGF Drug Production Value Comparison
  4.1.1 United States VS China: Anti-VEGF Drug Production Value Comparison (2018 & 2022 & 2029)
  4.1.2 United States VS China: Anti-VEGF Drug Production Value Market Share Comparison (2018 & 2022 & 2029)
4.2 United States VS China: Anti-VEGF Drug Production Comparison
  4.2.1 United States VS China: Anti-VEGF Drug Production Comparison (2018 & 2022 & 2029)
  4.2.2 United States VS China: Anti-VEGF Drug Production Market Share Comparison (2018 & 2022 & 2029)
4.3 United States VS China: Anti-VEGF Drug Consumption Comparison
  4.3.1 United States VS China: Anti-VEGF Drug Consumption Comparison (2018 & 2022 & 2029)
  4.3.2 United States VS China: Anti-VEGF Drug Consumption Market Share Comparison (2018 & 2022 & 2029)
4.4 United States Based Anti-VEGF Drug Manufacturers and Market Share, 2018-2023
  4.4.1 United States Based Anti-VEGF Drug Manufacturers, Headquarters and Production Site (States, Country)
  4.4.2 United States Based Manufacturers Anti-VEGF Drug Production Value (2018-2023)
  4.4.3 United States Based Manufacturers Anti-VEGF Drug Production (2018-2023)
4.5 China Based Anti-VEGF Drug Manufacturers and Market Share
  4.5.1 China Based Anti-VEGF Drug Manufacturers, Headquarters and Production Site (Province, Country)
  4.5.2 China Based Manufacturers Anti-VEGF Drug Production Value (2018-2023)
  4.5.3 China Based Manufacturers Anti-VEGF Drug Production (2018-2023)
4.6 Rest of World Based Anti-VEGF Drug Manufacturers and Market Share, 2018-2023
  4.6.1 Rest of World Based Anti-VEGF Drug Manufacturers, Headquarters and Production Site (State, Country)
  4.6.2 Rest of World Based Manufacturers Anti-VEGF Drug Production Value (2018-2023)
  4.6.3 Rest of World Based Manufacturers Anti-VEGF Drug Production (2018-2023)

5 MARKET ANALYSIS BY TYPE

5.1 World Anti-VEGF Drug Market Size Overview by Type: 2018 VS 2022 VS 2029
5.2 Segment Introduction by Type
  5.2.1 Avastin
  5.2.2 Lucentis
  5.2.3 Eylea
5.3 Market Segment by Type
  5.3.1 World Anti-VEGF Drug Production by Type (2018-2029)
  5.3.2 World Anti-VEGF Drug Production Value by Type (2018-2029)
  5.3.3 World Anti-VEGF Drug Average Price by Type (2018-2029)

6 MARKET ANALYSIS BY APPLICATION

6.1 World Anti-VEGF Drug Market Size Overview by Application: 2018 VS 2022 VS 2029
6.2 Segment Introduction by Application
  6.2.1 Age-related Macular Degeneration
  6.2.2 Macular Edema Following Retinal Vein Occlusion
  6.2.3 Diabetic Macular Edema
  6.2.4 Diabetic Retinopathy
6.3 Market Segment by Application
  6.3.1 World Anti-VEGF Drug Production by Application (2018-2029)
  6.3.2 World Anti-VEGF Drug Production Value by Application (2018-2029)
  6.3.3 World Anti-VEGF Drug Average Price by Application (2018-2029)

7 COMPANY PROFILES

7.1 F. Hoffmann-La Roche Ltd
  7.1.1 F. Hoffmann-La Roche Ltd Details
  7.1.2 F. Hoffmann-La Roche Ltd Major Business
  7.1.3 F. Hoffmann-La Roche Ltd Anti-VEGF Drug Product and Services
  7.1.4 F. Hoffmann-La Roche Ltd Anti-VEGF Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
  7.1.5 F. Hoffmann-La Roche Ltd Recent Developments/Updates
  7.1.6 F. Hoffmann-La Roche Ltd Competitive Strengths & Weaknesses
7.2 Amgen Inc
  7.2.1 Amgen Inc Details
  7.2.2 Amgen Inc Major Business
  7.2.3 Amgen Inc Anti-VEGF Drug Product and Services
  7.2.4 Amgen Inc Anti-VEGF Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
  7.2.5 Amgen Inc Recent Developments/Updates
  7.2.6 Amgen Inc Competitive Strengths & Weaknesses
7.3 Pfizer, Inc
  7.3.1 Pfizer, Inc Details
  7.3.2 Pfizer, Inc Major Business
  7.3.3 Pfizer, Inc Anti-VEGF Drug Product and Services
  7.3.4 Pfizer, Inc Anti-VEGF Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
  7.3.5 Pfizer, Inc Recent Developments/Updates
  7.3.6 Pfizer, Inc Competitive Strengths & Weaknesses
7.4 Xbrane Biopharma AB
  7.4.1 Xbrane Biopharma AB Details
  7.4.2 Xbrane Biopharma AB Major Business
  7.4.3 Xbrane Biopharma AB Anti-VEGF Drug Product and Services
  7.4.4 Xbrane Biopharma AB Anti-VEGF Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
  7.4.5 Xbrane Biopharma AB Recent Developments/Updates
  7.4.6 Xbrane Biopharma AB Competitive Strengths & Weaknesses
7.5 Allergan
  7.5.1 Allergan Details
  7.5.2 Allergan Major Business
  7.5.3 Allergan Anti-VEGF Drug Product and Services
  7.5.4 Allergan Anti-VEGF Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
  7.5.5 Allergan Recent Developments/Updates
  7.5.6 Allergan Competitive Strengths & Weaknesses
7.6 Bayer AG
  7.6.1 Bayer AG Details
  7.6.2 Bayer AG Major Business
  7.6.3 Bayer AG Anti-VEGF Drug Product and Services
  7.6.4 Bayer AG Anti-VEGF Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
  7.6.5 Bayer AG Recent Developments/Updates
  7.6.6 Bayer AG Competitive Strengths & Weaknesses
7.7 Regeneron Pharmaceuticals Inc.
  7.7.1 Regeneron Pharmaceuticals Inc. Details
  7.7.2 Regeneron Pharmaceuticals Inc. Major Business
  7.7.3 Regeneron Pharmaceuticals Inc. Anti-VEGF Drug Product and Services
  7.7.4 Regeneron Pharmaceuticals Inc. Anti-VEGF Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
  7.7.5 Regeneron Pharmaceuticals Inc. Recent Developments/Updates
  7.7.6 Regeneron Pharmaceuticals Inc. Competitive Strengths & Weaknesses
7.8 Viatris Inc
  7.8.1 Viatris Inc Details
  7.8.2 Viatris Inc Major Business
  7.8.3 Viatris Inc Anti-VEGF Drug Product and Services
  7.8.4 Viatris Inc Anti-VEGF Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
  7.8.5 Viatris Inc Recent Developments/Updates
  7.8.6 Viatris Inc Competitive Strengths & Weaknesses

8 INDUSTRY CHAIN ANALYSIS

8.1 Anti-VEGF Drug Industry Chain
8.2 Anti-VEGF Drug Upstream Analysis
  8.2.1 Anti-VEGF Drug Core Raw Materials
  8.2.2 Main Manufacturers of Anti-VEGF Drug Core Raw Materials
8.3 Midstream Analysis
8.4 Downstream Analysis
8.5 Anti-VEGF Drug Production Mode
8.6 Anti-VEGF Drug Procurement Model
8.7 Anti-VEGF Drug Industry Sales Model and Sales Channels
  8.7.1 Anti-VEGF Drug Sales Model
  8.7.2 Anti-VEGF Drug Typical Customers

9 RESEARCH FINDINGS AND CONCLUSION

10 APPENDIX

10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. World Anti-VEGF Drug Production Value by Region (2018, 2022 and 2029) & (USD Million)
Table 2. World Anti-VEGF Drug Production Value by Region (2018-2023) & (USD Million)
Table 3. World Anti-VEGF Drug Production Value by Region (2024-2029) & (USD Million)
Table 4. World Anti-VEGF Drug Production Value Market Share by Region (2018-2023)
Table 5. World Anti-VEGF Drug Production Value Market Share by Region (2024-2029)
Table 6. World Anti-VEGF Drug Production by Region (2018-2023) & (K Units)
Table 7. World Anti-VEGF Drug Production by Region (2024-2029) & (K Units)
Table 8. World Anti-VEGF Drug Production Market Share by Region (2018-2023)
Table 9. World Anti-VEGF Drug Production Market Share by Region (2024-2029)
Table 10. World Anti-VEGF Drug Average Price by Region (2018-2023) & (US$/Unit)
Table 11. World Anti-VEGF Drug Average Price by Region (2024-2029) & (US$/Unit)
Table 12. Anti-VEGF Drug Major Market Trends
Table 13. World Anti-VEGF Drug Consumption Growth Rate Forecast by Region (2018 & 2022 & 2029) & (K Units)
Table 14. World Anti-VEGF Drug Consumption by Region (2018-2023) & (K Units)
Table 15. World Anti-VEGF Drug Consumption Forecast by Region (2024-2029) & (K Units)
Table 16. World Anti-VEGF Drug Production Value by Manufacturer (2018-2023) & (USD Million)
Table 17. Production Value Market Share of Key Anti-VEGF Drug Producers in 2022
Table 18. World Anti-VEGF Drug Production by Manufacturer (2018-2023) & (K Units)
Table 19. Production Market Share of Key Anti-VEGF Drug Producers in 2022
Table 20. World Anti-VEGF Drug Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 21. Global Anti-VEGF Drug Company Evaluation Quadrant
Table 22. World Anti-VEGF Drug Industry Rank of Major Manufacturers, Based on Production Value in 2022
Table 23. Head Office and Anti-VEGF Drug Production Site of Key Manufacturer
Table 24. Anti-VEGF Drug Market: Company Product Type Footprint
Table 25. Anti-VEGF Drug Market: Company Product Application Footprint
Table 26. Anti-VEGF Drug Competitive Factors
Table 27. Anti-VEGF Drug New Entrant and Capacity Expansion Plans
Table 28. Anti-VEGF Drug Mergers & Acquisitions Activity
Table 29. United States VS China Anti-VEGF Drug Production Value Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 30. United States VS China Anti-VEGF Drug Production Comparison, (2018 & 2022 & 2029) & (K Units)
Table 31. United States VS China Anti-VEGF Drug Consumption Comparison, (2018 & 2022 & 2029) & (K Units)
Table 32. United States Based Anti-VEGF Drug Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers Anti-VEGF Drug Production Value, (2018-2023) & (USD Million)
Table 34. United States Based Manufacturers Anti-VEGF Drug Production Value Market Share (2018-2023)
Table 35. United States Based Manufacturers Anti-VEGF Drug Production (2018-2023) & (K Units)
Table 36. United States Based Manufacturers Anti-VEGF Drug Production Market Share (2018-2023)
Table 37. China Based Anti-VEGF Drug Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers Anti-VEGF Drug Production Value, (2018-2023) & (USD Million)
Table 39. China Based Manufacturers Anti-VEGF Drug Production Value Market Share (2018-2023)
Table 40. China Based Manufacturers Anti-VEGF Drug Production (2018-2023) & (K Units)
Table 41. China Based Manufacturers Anti-VEGF Drug Production Market Share (2018-2023)
Table 42. Rest of World Based Anti-VEGF Drug Manufacturers, Headquarters and Production Site (States, Country)
Table 43. Rest of World Based Manufacturers Anti-VEGF Drug Production Value, (2018-2023) & (USD Million)
Table 44. Rest of World Based Manufacturers Anti-VEGF Drug Production Value Market Share (2018-2023)
Table 45. Rest of World Based Manufacturers Anti-VEGF Drug Production (2018-2023) & (K Units)
Table 46. Rest of World Based Manufacturers Anti-VEGF Drug Production Market Share (2018-2023)
Table 47. World Anti-VEGF Drug Production Value by Type, (USD Million), 2018 & 2022 & 2029
Table 48. World Anti-VEGF Drug Production by Type (2018-2023) & (K Units)
Table 49. World Anti-VEGF Drug Production by Type (2024-2029) & (K Units)
Table 50. World Anti-VEGF Drug Production Value by Type (2018-2023) & (USD Million)
Table 51. World Anti-VEGF Drug Production Value by Type (2024-2029) & (USD Million)
Table 52. World Anti-VEGF Drug Average Price by Type (2018-2023) & (US$/Unit)
Table 53. World Anti-VEGF Drug Average Price by Type (2024-2029) & (US$/Unit)
Table 54. World Anti-VEGF Drug Production Value by Application, (USD Million), 2018 & 2022 & 2029
Table 55. World Anti-VEGF Drug Production by Application (2018-2023) & (K Units)
Table 56. World Anti-VEGF Drug Production by Application (2024-2029) & (K Units)
Table 57. World Anti-VEGF Drug Production Value by Application (2018-2023) & (USD Million)
Table 58. World Anti-VEGF Drug Production Value by Application (2024-2029) & (USD Million)
Table 59. World Anti-VEGF Drug Average Price by Application (2018-2023) & (US$/Unit)
Table 60. World Anti-VEGF Drug Average Price by Application (2024-2029) & (US$/Unit)
Table 61. F. Hoffmann-La Roche Ltd Basic Information, Manufacturing Base and Competitors
Table 62. F. Hoffmann-La Roche Ltd Major Business
Table 63. F. Hoffmann-La Roche Ltd Anti-VEGF Drug Product and Services
Table 64. F. Hoffmann-La Roche Ltd Anti-VEGF Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 65. F. Hoffmann-La Roche Ltd Recent Developments/Updates
Table 66. F. Hoffmann-La Roche Ltd Competitive Strengths & Weaknesses
Table 67. Amgen Inc Basic Information, Manufacturing Base and Competitors
Table 68. Amgen Inc Major Business
Table 69. Amgen Inc Anti-VEGF Drug Product and Services
Table 70. Amgen Inc Anti-VEGF Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 71. Amgen Inc Recent Developments/Updates
Table 72. Amgen Inc Competitive Strengths & Weaknesses
Table 73. Pfizer, Inc Basic Information, Manufacturing Base and Competitors
Table 74. Pfizer, Inc Major Business
Table 75. Pfizer, Inc Anti-VEGF Drug Product and Services
Table 76. Pfizer, Inc Anti-VEGF Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 77. Pfizer, Inc Recent Developments/Updates
Table 78. Pfizer, Inc Competitive Strengths & Weaknesses
Table 79. Xbrane Biopharma AB Basic Information, Manufacturing Base and Competitors
Table 80. Xbrane Biopharma AB Major Business
Table 81. Xbrane Biopharma AB Anti-VEGF Drug Product and Services
Table 82. Xbrane Biopharma AB Anti-VEGF Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 83. Xbrane Biopharma AB Recent Developments/Updates
Table 84. Xbrane Biopharma AB Competitive Strengths & Weaknesses
Table 85. Allergan Basic Information, Manufacturing Base and Competitors
Table 86. Allergan Major Business
Table 87. Allergan Anti-VEGF Drug Product and Services
Table 88. Allergan Anti-VEGF Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 89. Allergan Recent Developments/Updates
Table 90. Allergan Competitive Strengths & Weaknesses
Table 91. Bayer AG Basic Information, Manufacturing Base and Competitors
Table 92. Bayer AG Major Business
Table 93. Bayer AG Anti-VEGF Drug Product and Services
Table 94. Bayer AG Anti-VEGF Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 95. Bayer AG Recent Developments/Updates
Table 96. Bayer AG Competitive Strengths & Weaknesses
Table 97. Regeneron Pharmaceuticals Inc. Basic Information, Manufacturing Base and Competitors
Table 98. Regeneron Pharmaceuticals Inc. Major Business
Table 99. Regeneron Pharmaceuticals Inc. Anti-VEGF Drug Product and Services
Table 100. Regeneron Pharmaceuticals Inc. Anti-VEGF Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 101. Regeneron Pharmaceuticals Inc. Recent Developments/Updates
Table 102. Viatris Inc Basic Information, Manufacturing Base and Competitors
Table 103. Viatris Inc Major Business
Table 104. Viatris Inc Anti-VEGF Drug Product and Services
Table 105. Viatris Inc Anti-VEGF Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 106. Global Key Players of Anti-VEGF Drug Upstream (Raw Materials)
Table 107. Anti-VEGF Drug Typical Customers
Table 108. Anti-VEGF Drug Typical Distributors

List Of Figures

LIST OF FIGURES

Figure 1. Anti-VEGF Drug Picture
Figure 2. World Anti-VEGF Drug Production Value: 2018 & 2022 & 2029, (USD Million)
Figure 3. World Anti-VEGF Drug Production Value and Forecast (2018-2029) & (USD Million)
Figure 4. World Anti-VEGF Drug Production (2018-2029) & (K Units)
Figure 5. World Anti-VEGF Drug Average Price (2018-2029) & (US$/Unit)
Figure 6. World Anti-VEGF Drug Production Value Market Share by Region (2018-2029)
Figure 7. World Anti-VEGF Drug Production Market Share by Region (2018-2029)
Figure 8. North America Anti-VEGF Drug Production (2018-2029) & (K Units)
Figure 9. Europe Anti-VEGF Drug Production (2018-2029) & (K Units)
Figure 10. China Anti-VEGF Drug Production (2018-2029) & (K Units)
Figure 11. Japan Anti-VEGF Drug Production (2018-2029) & (K Units)
Figure 12. Anti-VEGF Drug Market Drivers
Figure 13. Factors Affecting Demand
Figure 14. World Anti-VEGF Drug Consumption (2018-2029) & (K Units)
Figure 15. World Anti-VEGF Drug Consumption Market Share by Region (2018-2029)
Figure 16. United States Anti-VEGF Drug Consumption (2018-2029) & (K Units)
Figure 17. China Anti-VEGF Drug Consumption (2018-2029) & (K Units)
Figure 18. Europe Anti-VEGF Drug Consumption (2018-2029) & (K Units)
Figure 19. Japan Anti-VEGF Drug Consumption (2018-2029) & (K Units)
Figure 20. South Korea Anti-VEGF Drug Consumption (2018-2029) & (K Units)
Figure 21. ASEAN Anti-VEGF Drug Consumption (2018-2029) & (K Units)
Figure 22. India Anti-VEGF Drug Consumption (2018-2029) & (K Units)
Figure 23. Producer Shipments of Anti-VEGF Drug by Manufacturer Revenue ($MM) and Market Share (%): 2022
Figure 24. Global Four-firm Concentration Ratios (CR4) for Anti-VEGF Drug Markets in 2022
Figure 25. Global Four-firm Concentration Ratios (CR8) for Anti-VEGF Drug Markets in 2022
Figure 26. United States VS China: Anti-VEGF Drug Production Value Market Share Comparison (2018 & 2022 & 2029)
Figure 27. United States VS China: Anti-VEGF Drug Production Market Share Comparison (2018 & 2022 & 2029)
Figure 28. United States VS China: Anti-VEGF Drug Consumption Market Share Comparison (2018 & 2022 & 2029)
Figure 29. United States Based Manufacturers Anti-VEGF Drug Production Market Share 2022
Figure 30. China Based Manufacturers Anti-VEGF Drug Production Market Share 2022
Figure 31. Rest of World Based Manufacturers Anti-VEGF Drug Production Market Share 2022
Figure 32. World Anti-VEGF Drug Production Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 33. World Anti-VEGF Drug Production Value Market Share by Type in 2022
Figure 34. Avastin
Figure 35. Lucentis
Figure 36. Eylea
Figure 37. World Anti-VEGF Drug Production Market Share by Type (2018-2029)
Figure 38. World Anti-VEGF Drug Production Value Market Share by Type (2018-2029)
Figure 39. World Anti-VEGF Drug Average Price by Type (2018-2029) & (US$/Unit)
Figure 40. World Anti-VEGF Drug Production Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 41. World Anti-VEGF Drug Production Value Market Share by Application in 2022
Figure 42. Age-related Macular Degeneration
Figure 43. Macular Edema Following Retinal Vein Occlusion
Figure 44. Diabetic Macular Edema
Figure 45. Diabetic Retinopathy
Figure 46. World Anti-VEGF Drug Production Market Share by Application (2018-2029)
Figure 47. World Anti-VEGF Drug Production Value Market Share by Application (2018-2029)
Figure 48. World Anti-VEGF Drug Average Price by Application (2018-2029) & (US$/Unit)
Figure 49. Anti-VEGF Drug Industry Chain
Figure 50. Anti-VEGF Drug Procurement Model
Figure 51. Anti-VEGF Drug Sales Model
Figure 52. Anti-VEGF Drug Sales Channels, Direct Sales, and Distribution
Figure 53. Methodology
Figure 54. Research Process and Data Source